Magnesium sulphate for fetal neuroprotection: A cost-effectiveness analysis

BMC Health Services Research

Volumn 13, Issue 1, 2013, Pages

  Bickford, Celeste D ^a   Magee, Laura A ^a   Mitton, Craig ^a   Kruse, Marie ^b   Synnes, Anne R ^c   Sawchuck, Diane ^a   Basso, Melanie ^c   Senikas, Vyta M ^d   Von Dadelszen, Peter ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Dansk Sundhedsinstitut   (Denmark)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Cerebral palsy; Cost effectiveness; Fetal neuroprotection; Magnesium sulphate; Preterm birth

Indexed keywords

MAGNESIUM SULFATE; NEUROPROTECTIVE AGENT;

ARTICLE; CEREBRAL PALSY; COST BENEFIT ANALYSIS; COST CONTROL; DECISION TREE; DRUG COST; DRUG EFFECT; ECONOMICS; FEMALE; FETUS; GESTATIONAL AGE; HEALTH CARE COST; HUMAN; PREGNANCY; PREMATURITY; PRENATAL CARE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK ASSESSMENT; STATISTICS; DRUG EFFECTS; PREMATURE BIRTH; STATISTICS AND NUMERICAL DATA;

CEREBRAL PALSY; COST SAVINGS; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG COSTS; FEMALE; FETUS; GESTATIONAL AGE; HEALTH CARE COSTS; HUMANS; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENTS; PREGNANCY; PREMATURE BIRTH; PRENATAL CARE; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT;

EID: 84890336592     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-13-527     Document Type: Article

References (35)

1. Lifetime costs of cerebral palsy. Kruse M, Michelsen SI, Flachs EM, Brønnum-Hansen H, Madsen M, Uldall P, Dev Med Child Neurol 2009 51 622 628
2. Quality of life and health-related quality of life of adolescents with cerebral palsy. Rosenbaum PL, Livingston MH, Palisano RJ, Galuppi BE, Russell DJ, Dev Med Child Neurol 2007 49 516 521 (Pubitemid 47018498)
3. The health and quality of life outcomes among youth and young adults with cerebral palsy. Young NL, Rochon TG, McCormick A, Law M, Wedge JH, Fehlings D, Arch Phys Med Rehabil 2010 91 143 148
4. Analysis by gestational age of cerebral palsy in singleton births in north-east England 1970-94. Drummond PM, Colver AF, Paediatr Perinat Epidemiol 2002 16 172 180 (Pubitemid 34492239)
5. Antenatal magnesium sulphate for the prevention of cerebral palsy in preterm infants < 34 weeks' gestation: a systematic review and metaanalysis. Conde-Agudelo A, Romero R, Am J Obstet Gynecol 2009 200 595 609
6. Effects of antenatal exposure to magnesium sulphate on neuroprotection and mortality in preterm infants: a meta-analysis. Costantine MM, Weiner SJ, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, Obstet Gynecol 2009 114 354 364
7. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Doyle LW, Crowther CA, Middleton P, Marret S, Cochrane Database Syst Rev 2009 3 CD004661
8. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomized controlled PREMAG trial. Marret S, Marpeau L, Zupan-Simunek V, Eurin D, Lévêque C, Hellot MF, Bénichou J, PREMAG trial group, BJOG 2007 114 310 318
9. Association between the use of antenatal magnesium sulphate in preterm labor and adverse health outcomes in infants. Mittendorf R, Dambrosia J, Pryde PG, Lee KS, Gianopoulos JG, Besinger RE, Tomich PG, Am J Obstet Gynecol 2002 186 1111 1118 (Pubitemid 34665044)
10. Effect of magnesium sulphate given for neuroprotection before preterm birth: a randomized controlled trial. Crowther CA, Hiller JE, Doyle LW, Haslam RR, Australasian Collaborative Trial of Magnesium Sulphate (ACTOMg SO4) Collaborative Group, JAMA 2003 290 2669 2676 (Pubitemid 37475594)
11. A randomized, controlled trial of magnesium sulphate for the prevention of cerebral palsy. Rouse DJ, Hirtz DG, Thom E, Varner MW, Spong CY, Mercer BM, Iams JD, Wapner RJ, Sorokin Y, Alexander JM, Harper M, Thorp JM Jr, Ramin SM, Malone FD, Carpenter M, Miodovnik M, Moawad A, O'Sullivan MJ, Peaceman AM, Hankins GD, Langer O, Caritis SN, Roberts JM, Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network, N Engl J Med 2008 359 895 905
12. Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel, Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: national clinical practice guidelines Adelaide: The University of Adelaide 2010
13. SOGC Clinical Practice Guideline. magnesium sulphate for fetal neuroprotection. Magee LA, Sawchuck D, Synnes A, von Dadelszen P, J Obstet Gynaecol Can 2011 33 516 529
14. Committee Opinion No. 455: magnesium sulphate before anticipated preterm birth for neuroprotection. American College of Obstetricians and Gynecologists Committee on Obstetric Practice, Society for Maternal-Fetal Medicine, Obstet Gynecol 2010 115 669 671
15. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. Magee LA, von Dadelszen P, Allen VM, Ansermino JM, Audibert F, Barrett J, Brant R, Bujold E, Crane JM, Demianczuk N, Joseph KS, Lee SK, Piedboeuf B, Smith G, Synnes A, Walker M, Whittle W, Wood S, Lee T, Li J, Payne B, Liston RM, Canadian Perinatal Network Collaborative Group, J Obstet Gynaecol Can 2011 33 111 120
16. Palisano R, Rosenbaum P, Bartlett D, Livingston M, Gross motor function classification system-expanded and revised Hamilton: CanChild Centre for Childhood Disability Research 2007
17. Life expectancy in severe cerebral palsy. Hutton JL, Pharoah PO, Arch Dis Child 2006 91 254 258 (Pubitemid 43325507)
18. Long-term survival for a cohort of adults with cerebral palsy. Hemming K, Hutton JL, Pharoah PO, Dev Med Child Neurol 2006 48 90 95 (Pubitemid 43125652)
19. Statistics Canada, Life expectancy, abridged life table, at birth and at age 65, by sex, Canada, provinces and territories, annual (years) (CANSIM Table 102-0512) Ottawa: Statistics Canada 2010
20. The Health Utilities Index (HUI): concepts, measurement properties and applications. Horsman J, Furlong W, Feeny W, Torrence G, Health Qual Life Outcomes 2003 1 54
21. Health status in survivors of cancer in childhood and adolescence. Pogany L, Barr RD, Shaw A, Speechley KN, Barrera M, Maunsell E, Qual Life Res 2006 15 143 157 (Pubitemid 43097594)
22. US norms for six generic health-related quality-of-life indexes from the National Health Measurement study. Fryback DG, Dunham NC, Palta M, Hanmer J, Buechner J, Cherepanov D, Herrington SA, Hays RD, Kaplan RM, Ganiats TG, Feeny D, Kind P, Med Care 2007 45 1162 1170
23. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. The Magpie Trial Collaborative Group, Lancet 2002 359 1877 1890
24. British Columbia Ministry of Health, Medical Services Commission payment schedule Vancouver: British Columbia Ministry of Health 2011
25. Iatrogenic acute hypermagnesemia after total parenteral nutrition infusion mimicking septic shock syndrome: two case reports. Ali A, Walentik C, Mantych GJ, Sadiq HF, Keenan WJ, Noguchi A, Pediatrics 2003 112 70 72
26. The clinical and biochemical effects of excess magnesium in the newborn. Lipsitz PJ, Pediatrics 1971 47 501 509
27. Association of cord blood magnesium concentration and neonatal resuscitation. Johnson LH, Mapp DC, Rouse DJ, Spong CY, Mercer BM, Leveno KJ, Varner MW, Iams JD, Sorokin Y, Ramin SM, Miodovnik M, O'Sullivan MJ, Peaceman AM, Caritis SN, Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network, J Pediatr 2012 160 573 577
28. Lee S, Anderson L, BC Perinatal services costing project: report on costs in the neonatal intensive care unit Vancouver: British Columbia Research Institute for Children's and Women's Health 2004
29. Briggs A, Sculpher M, Claxton C, Decision modelling for health economic evaluation Oxford: Oxford University Press 2006
30. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL, Methods for the economic evaluation of health care programmes Oxford: Oxford University Press 3 2005
31. Tan-Torres E, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJ, Making choices in health: WHO guide to cost-effectiveness analysis Geneva: World Health Organization 2003
32. National Institute for Health and Clinical Excellence, Briefing paper for the Methods Working Party on the cost effectiveness threshold London: National Institute for Health and Clinical Excellence 2007
33. Antenatal magnesium sulphate may prevent cerebral palsy in preterm infants-but are we convinced? Evaluation of an apparently conclusive meta-analysis with trial sequential analysis. Huusom LD, Secher NJ, Pryds O, Whitfield K, Gluud C, Brok J, BJOG 2011 118 1 5
34. Treatment with magnesium sulphate in pre-term birth: a systematic review and meta-analysis of observational studies. Wolf HT, Hegaard HK, Greisen G, Huusom L, Hedegaard M, J Obstet Gynaecol 2012 32 135 140
35. Magnesium sulfate therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic analysis. Cahill AG, Odibo AO, Stout MJ, Grobman WA, Macones GA, Caughey AB, Am J Obstet Gynecol 2011 205 542.e1 7